文献速递肝胆胰外科胃肠外科围术期管理与 ERAS

胰腺导管腺癌术前治疗后主要病理缓解的预后影响:739例多中心回顾性研究

Prognostic Impact of Major Pathologic Response After Preoperative Treatment in Resected Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Retrospective Study of 739 Cases.
PubMed 文献 · Ann Surg · 2026-03-18

该多中心回顾性研究分析了日本21家机构739例术前治疗后行胰腺切除术的PDAC患者,采用Evans分级定义主要病理缓解(MPR)为III/IV级。MPR组中位总生存(71.5 vs 40.9个月)和无复发生存(55.5 vs 15.2个月)显著优于非MPR组,MPR为独立预后因素;MPR亚组中辅助化疗未显示生存获益。

要点

  • MPR(Evans III/IV级)与显著延长的总生存和无复发生存独立相关。
  • MPR组中辅助化疗未显示独立预后获益,提示可个体化术后管理。
  • 同步放化疗、术前治疗≥6个月、CA19-9正常化和影像学缓解预测MPR。

核心结论

  • MPR是PDAC术前治疗后独立良好预后因素。
  • MPR患者中辅助化疗的预后影响未观察到,提示MPR可指导个体化术后管理,需前瞻性验证。

研究设计与样本

  • 多中心回顾性研究,纳入日本21家机构739例术前治疗后行胰腺切除术的PDAC患者。
  • 病理反应采用Evans分级,MPR定义为III/IV级。

主要发现

  • 11.5%患者达到MPR。
  • MPR组中位总生存71.5个月 vs 非MPR组40.9个月。
  • MPR组中位无复发生存55.5个月 vs 非MPR组15.2个月。
  • 多因素分析显示MPR为总生存的独立预后因素。
  • MPR亚组中辅助化疗与否总生存和无复发生存无差异,多因素分析未显示辅助治疗为独立预后因素。

关键数值与推荐

  • MPR预测因素包括:同步放化疗、术前治疗持续时间≥6个月、术前治疗后CA19-9正常、影像学完全或部分缓解。
  • 研究开发了简化的MPR预测模型。

临床怎么用

  • 术后病理达到MPR的患者预后显著较好,可考虑个体化术后管理策略。
  • 对于MPR患者,辅助化疗的绝对获益可能有限,需结合其他因素综合决策。

局限性

  • 回顾性研究设计。
  • MPR预测模型需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated the prognostic significance and implications of a major pathologic response (MPR) after preoperative treatment for pancreatic ductal adenocarcinoma (PDAC). SUMMARY BACKGROUND DATA: Preoperative treatment is increasingly used for PDAC to improve oncologic outcomes. The pathologic response represents a potential indicator of treatment efficacy; however, its prognostic value in PDAC remains unclear. METHODS: We retrospectively analyzed 739 patients who underwent pancreatectomy for PDAC after preoperative treatment at 21 institutions in Japan. The pathologic response was graded using Evans' classification, with MPR defined as Evans grade III/IV. Survival outcomes and prognostic factors were evaluated, and factors associated with achieving MPR were analyzed to develop a predictive model. RESULTS: MPR was achieved in 11.5% of patients. The MPR group had a significantly longer median overall survival (71.5 vs. 40.9 mo) and recurrence-free survival (55.5 vs. 15.2 mo) than the non-MPR group. Multivariate analysis identified MPR as an independent prognostic factor for overall survival. In the MPR subgroup, neither overall nor recurrence-free survival differed according to adjuvant chemotherapy administration; multivariate analysis did not identify adjuvant therapy as an independent prognostic factor. Predictive factors for achieving MPR included chemoradiotherapy, preoperative duration ≥6 months, normal carbohydrate antigen 19-9 after preoperative treatment, and complete or partial radiologic response. Finally, we developed a simplified predictive model for achieving MPR. CONCLUSIONS: MPR was independently associated with favorable survival in PDAC. The prognostic impact of adjuvant chemotherapy was not observed among patients who achieved MPR, suggesting that MPR may inform individualized postoperative management and warrants prospective validation.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Yamane K, Nagai K, Anazawa T, et al. Prognostic Impact of Major Pathologic Response After Preoperative Treatment in Resected Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Retrospective Study of 739 Cases. Ann Surg. 2026. PMID: 41843644. doi:10.1097/SLA.0000000000007052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。